about
Phospholipase C delta-4 overexpression upregulates ErbB1/2 expression, Erk signaling pathway, and proliferation in MCF-7 cellsExpression of lysophosphatidic acid acyltransferase beta (LPAAT-beta) in ovarian carcinoma: correlation with tumour grading and prognosisPixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial.Procoagulant inhibitory properties of paclitaxel poliglumex.Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane.Paclitaxel poliglumex (XYOTAX, CT-2103): a macromolecular taxane.Phosphatidic acid signaling mediates lung cytokine expression and lung inflammatory injury after hemorrhage in mice.The Use of Genetic Markers in Studies of Myeloid Neoplasia.Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib.Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomas.Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors.Synthesis, SAR, and antitumor properties of diamino-C,N-diarylpyrimidine positional isomers: inhibitors of lysophosphatidic acid acyltransferase-beta.rhGM-CSF after allogeneic bone marrow transplantation from unrelated donors: a pilot study of cyclosporine and prednisone as graft-versus-host disease prophylaxis.The use of recombinant human granulocyte macrophage colony-stimulating factor in autologous and allogeneic bone marrow transplantation.Correlation between cytogenetic and molecular findings in human chronic myelogenous leukemia lines EM-2 and EM-3.Donor origin of the in vitro haematopoietic microenvironment after marrow transplantation in man.Water-soluble poly-(L-glutamic acid)-Gly-camptothecin conjugates enhance camptothecin stability and efficacy in vivo.The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients.An increase in serum C18 unsaturated free fatty acids as a predictor of the development of acute respiratory distress syndrome.Synthesis and in vivo antitumor activity of poly(l-glutamic acid) conjugates of 20S-camptothecin.Bone marrow transplantation in a patient with myelodysplasia associated with diffuse eosinophilic fasciitis.Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials.Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression.Comparison of pixantrone-based regimen (CPOP-R) with doxorubicin-based therapy (CHOP-R) for treatment of diffuse large B-cell lymphoma.Effect of GM-CSF on circulating granulocyte-monocyte progenitors in autologous bone marrow transplantation.Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer.Diamino-C,N-diarylpyridine positional isomers as inhibitors of lysophosphatidic acid acyltransferase-beta.Responsiveness of the in vitro hematopoietic microenvironment to platelet-derived growth factor.Evidence for a stem cell common to hematopoiesis and its in vitro microenvironment: studies of patients with clonal hematopoietic neoplasia.Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer.Preferential radiosensitization of G1 checkpoint-deficient cells by methylxanthines.Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphomaPrevalence of clinically relevant bacteremia after upper gastrointestinal endoscopy in bone marrow transplant recipientsChronic lymphocytosis with neutropenia: evidence for a novel, abnormal T-cell population associated with antibody-mediated neutrophil destructionAnthracycline cardiotoxicity: clinical and pathologic outcomes assessed by radionuclide ejection fractionTreatment of chronic granulocytic leukaemia in chronic phase by allogeneic marrow transplantationLisofylline suppresses ex vivo release by murine spleen cells of hematopoietic inhibitors induced by cancer chemotherapeutic agentsLysophosphatidic acid acyltransferase-beta (LPAAT-beta) is highly expressed in advanced ovarian cancer and is associated with aggressive histology and poor survivalRadiopharmaceutical reimbursement ratesA phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors
P50
Q21245746-A554B7F2-F335-496B-9EAE-D7CB15EC6645Q24650522-F61B43B8-9FF3-469E-9614-56574CD6A5FBQ33401543-5AF34A36-B73B-48B6-B0B0-AF71580F966BQ34665903-CFFA039D-72E4-4506-B564-AD7C3A4625A4Q36041856-84B04006-15F9-4AE3-933A-46CC28409780Q36317237-F4E2DD46-254E-4188-9F8D-B912257F5FF9Q36364411-546078E7-3E93-424E-8EA5-C53438912653Q38908385-3DB1F1A0-FC94-4262-8A6C-5151FA27D1FBQ40211807-1CD7AD8C-A6C6-4EB4-B8D4-34B2B7A92D5DQ40401154-903F40C0-9E91-4F05-B519-C83BF91523CCQ40453614-D7A23C80-42A4-4754-B777-F6972DA1BBB6Q40567515-15B463E9-8634-4B87-8E11-FE783955DBB5Q40717425-E9115FBF-7D68-461E-B399-829F4C48DC1BQ40891338-66B6063F-1A0F-40E2-9C9F-DF42380C3CD0Q41823325-DD4074D4-50D8-4114-96D0-71D5183755B7Q42463848-C0652210-A72D-48F0-AA47-18DE8CEE84B0Q43698657-2112359D-9765-4230-B6EA-E855619958A5Q43906042-4E3D8193-6EF0-402E-8C0E-078880F97502Q44230000-7C357A5A-4E12-4E04-9112-537F986D18A1Q44262364-52319463-A400-43E6-95EA-D2211762A26EQ44501823-29002937-5DC8-4C80-8EF6-E9DF6FA2CD31Q44885041-7242BC7E-9E33-464A-A375-01BA414DFB62Q44941336-395F495D-F459-4DE5-B869-82B89DDC53D7Q44950915-B099A928-BEEC-4842-8D1F-B6DA8DC78B48Q46075317-D3CBAADD-ECB5-46FB-A343-12ED7E4F7B5BQ46507139-70B610CB-46F2-4C0F-9F15-1956228E552CQ46688241-556A2253-0767-402B-80B3-D2CDB46FB9CFQ47648374-762AD3A9-AB3B-438E-A048-E35BF6C366D8Q47649252-49FEFE10-D5F3-4F21-AD91-B2FD8A296345Q53144257-0F88482A-56F0-4D9C-BB79-76570F46760DQ54192734-10CCFE53-FCAE-42F9-BD63-38AF6B04D2D6Q61758305-E6DFA029-8E89-4791-A79B-E032E5EABCDEQ68880167-59D3ACE3-84DA-4FCC-B3D3-EB6AAB452ACEQ70990169-20C39D0C-62F4-4C67-8B3A-4EBED16D54DCQ72001401-DCB319B7-45C3-48FE-BEB1-717679736961Q72533144-A9C0DD13-995D-4B07-86B7-A90022A754E0Q74317765-DE15BA11-8642-41FD-AABC-52D6C97A1025Q80195184-22BFBC12-631E-43A4-82AB-A8F07528963CQ81394739-8058B7B1-8696-47D9-9C2D-EC4FEDB1C419Q81747738-66F288B4-E7A5-4067-9A7B-3B6342E18981
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Jack W. Singer
@ast
Jack W. Singer
@en
Jack W. Singer
@es
Jack W. Singer
@sl
type
label
Jack W. Singer
@ast
Jack W. Singer
@en
Jack W. Singer
@es
Jack W. Singer
@sl
prefLabel
Jack W. Singer
@ast
Jack W. Singer
@en
Jack W. Singer
@es
Jack W. Singer
@sl
P106
P1153
7402619980
P21
P31
P496
0000-0003-4001-4549